



March 4, 2014

ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 13, 2014

LOS ANGELES, March 4, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2013 financial results on Thursday, March 13, 2014. ImmunoCellular will host a conference call and webcast to discuss its financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.



LIVE CALL: (877) 853-5636 (toll-free); conference code: 5866155

WEBCAST: Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Contact:

ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com

Photo - <http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO>

SOURCE ImmunoCellular Therapeutics, Ltd.

News Provided by Acquire Media